Adocia Prioritizes BioChaperone and Secures Cash Reserves Until Early Q2 2027
Adocia has released its Q1 2026 financial results, showing a cash balance of EUR 12.0 million as of March 31, with a quarterly cash burn of EUR 5.1 million. As typical for a clinical-stage biotech, revenue was zero for the period, compared to EUR 0.6 million a year earlier from an AdOral feasibility study. The Lyon-based company is reallocating its resources towards BioChaperone, now a priority following positive feasibility study results, and has suspended the clinical trial application submission for AdoShell. A EUR 6.0 million financing arrangement with Vester Finance extends its cash runway until the start of Q2 2027.
Adocia had a cash reserve of EUR 12.0 million on March 31, 2026, down from EUR 17.2 million on December 31, 2025. The cash burn for the first quarter amounted to EUR 5.1 million, compared to EUR 6.6 million in the first quarter of 2025 excluding financing. Revenue for the period was zero, down from EUR 0.6 million a year earlier.
This decline should be viewed in the context of the economic model of a clinical-stage biotech: revenues are inherently irregular and depend largely on partnerships, milestone payments, or feasibility studies. In the first quarter of 2025, revenues came from a feasibility study related to the AdOral technology with an undisclosed partner.
BioChaperone Becomes the Strategic Priority
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The major shift announced by Adocia concerns its resource allocation. The company now prioritizes the BioChaperone platform, following positive results from feasibility studies and the initiation of a new study. This platform aims to stabilize and enhance metabolic peptide formulations, in a market where diabetes and obesity treatments are moving towards peptide combinations, particularly involving GLP-1 and amylin. Adocia has initiated feasibility studies with three major undisclosed pharmaceutical companies, two of which have yielded positive results.
AdoShell Suspended, But Not Abandoned
In parallel, Adocia has suspended activities related to the clinical trial application submission for AdoShell with human pancreatic islets, initially planned for the third quarter of 2026. The company explains this decision by the priority given to BioChaperone and the need to reallocate its human and financial resources to this technology. However, the AdoShell program is not presented as abandoned: Adocia indicates that it could resume this clinical goal when its financial situation and human resources allow.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 0 millions d'euros
Quarterly revenue: 0 millions d'euros
Revenue growth: -97 %
Guidance from the release
« Au 30 septembre 2026, la Société disposait d'une trésorerie de 8,4 millions d'euros qui lui permettait de financer ses activités jusqu'au début du deuxième trimestre 2027 » ; « Cette opération, en prenant en compte l'utilisation complète de la convention d'avance en compte courant, ainsi que la réduction des coûts initiée par la Société depuis septembre 2026, permet d'étendre l'horizon de trésor
Risks mentioned
Dépendance critique au paiement d'étape de 20 millions de dollars conditionné à l'obtention de l'AMM de BioChaperone Lispro en Chine
Besoin de financement à court ou moyen terme et capacité à lever des fonds supplémentaires
Incertitudes des données cliniques futures et de l'évolution des marchés du diabète et de l'obésité
Opportunities identified
Paiement d'étape de 20 millions de dollars sous condition de l'approbation de BC Lispro en Chine avec redevances à deux chiffres
Accords de collaboration R&D monétisés avec les entreprises pharmaceutiques pour tester librement la technologie BioChaperone
Extension de l'horizon de trésorerie jusqu'au T1 2028 (voire 2029 si AMM obtenue) grâce à la levée de 7 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
